Clinical Trial: An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07161700) titled 'An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)' on Sept. 02.

Brief Summary: This is an open-label, monotherapy, extension study to evaluate the safety and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.

Study Start Date: Sept. 02

Study Type: INTERVENTIONAL

Condition: Major Depressive Disorder (MDD) Major Depressive Disorder With Anxious Distress

Intervention: DRUG: SPT-300

A prodrug of allopregnanolone, a small m...